`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`MYLAN PHARMACEUTICALS INC.,
`
`Petitioner
`
`v.
`
`POZEN INC. and HORIZON PHARMA USA, INC.,
`
`Patent Owners
`
`
`
`U.S. Patent No. 9,220,698 to Ault et al.
`
`
`Inter Partes Review IPR2017-01995
`
`
`
`DECLARATION OF DAVID C. METZ, M.D.
`
`1
`
`MYLAN PHARMS. INC. EXHIBIT 1091 PAGE 1
`
`
`
`DECLARATION OF DAVID C. METZ, M.D.
`
`1.
`
`I, David C. Metz, M.D., am over the age of eighteen and otherwise
`
`competent to make this Declaration. I have personal knowledge of the facts set
`
`forth in this Declaration and am competent to testify to the same.
`
`2.
`
`I have been retained by counsel for Petitioner Mylan Pharmaceuticals
`
`Inc. (“Mylan”) in connection with the above-captioned inter partes review
`
`(“IPR”).
`
`3.
`
`I
`
`am
`
`educated
`
`and
`
`experienced
`
`in medicine,
`
`including
`
`gastroenterology, as detailed in my previous Declaration that was filed with the
`
`Petition as Exhibit 1002, and my Curriculum Vitae filed as Exhibit A to Exhibit
`
`1002.
`
`4.
`
`Ex. 1010 is a true and correct copy of the 2004 approval letter and
`
`label for Zegerid, which were publicly available upon Zegerid’s approval on June
`
`16, 2004, and thus before 2007. In addition, news of approval of new medicines is
`
`commonly circulated among gastroenterologists, and I personally viewed the
`
`Zegerid label that is Ex. 1010 before 2007. I also prescribed Zegerid to my
`
`patients according to the label that is Ex. 1010 before 2007.
`
`
`
`2
`
`MYLAN PHARMS. INC. EXHIBIT 1091 PAGE 2
`
`
`
`DECLARATION OF DAVID C. METZ, M.D.
`
`
` hereby declare that all statements made herein of my own knowledge are
`
` I
`
`true and that all statements made on information and belief are believed to be true;
`
`and further that these statements were made with the knowledge that willful false
`
`statements and the like so made are punishable by fine or imprisonment, or both,
`
`under Section 1001 of Title 18 of the United States Code.
`
`
`Dated: April 5, 2018
`
`
`/David C. Metz, M.D./
`
`
`3
`
`MYLAN PHARMS. INC. EXHIBIT 1091 PAGE 3
`
`
`
`DECLARATION OF DAVID C. METZ, M.D.
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. § 42.6(e), I certify that I caused to be served a true and
`
`correct copy of the foregoing: DECLARATION OF DAVID C. METZ, M.D., by
`
`email to the electronic service addresses for Patent Owner:
`
`Thomas A. Blinka
`Jonathan G. Graves
`Susan Krumplitsch
`Cooley LLP
`zIPR2017-01995@cooley.com
`
`Margaret J. Sampson
`Stephen M. Hash
`Jeffrey S. Gritton
`Baker Botts LLP
`pozen-vimovoBB@bakerbotts.com
`
`Dated: April 5, 2018
`
`
`
`
`
`
`
`
`
`
`/Bryan D. Beel/
`
`Counsel for Petitioner Mylan Pharmaceuticals Inc.
`
`MYLAN PHARMS. INC. EXHIBIT 1091 PAGE 4
`
`